{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:28:31Z","timestamp":1793975311200,"version":"4.8.0"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bbrep.2026.102822","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:28:27Z","timestamp":1790832507000},"page":"102822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Engineered exosomes for breast cancer immunotherapy: Emerging strategies and translational potential"],"prefix":"10.1016","volume":"48","author":[{"given":"Niloufar","family":"Orooji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Ghasemian-Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamana","family":"Eskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrshad","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Tavassoli Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9876-4943","authenticated-orcid":false,"given":"Dariush","family":"Haghmorad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.bbrep.2026.102822_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121822","article-title":"Immunotherapy: a challenge of breast cancer treatment","volume":"11","author":"Garc\u00eda-Aranda","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"10440","key":"10.1016\/j.bbrep.2026.102822_bib3","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the global burden of disease study 2021","volume":"403","author":"Vollset","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib4","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(18)30488-1","article-title":"Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment","volume":"7","author":"Chen","year":"2019","journal-title":"Lancet Global Health"},{"issue":"10352","key":"10.1016\/j.bbrep.2026.102822_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","article-title":"The global burden of cancer attributable to risk factors, 2010\u201319: a systematic analysis for the global burden of disease study 2019","volume":"400","author":"Tran","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib6","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca - Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","article-title":"Key steps for effective breast cancer prevention","volume":"20","author":"Britt","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrep.2026.102822_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120499","article-title":"Photothermal therapy-mediated autophagy in breast cancer treatment: progress and trends","volume":"298","author":"Kadkhoda","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"npj Breast Cancer"},{"issue":"6","key":"10.1016\/j.bbrep.2026.102822_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/13543784.2021.1983542","article-title":"Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer","volume":"31","author":"Chen","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrep.2026.102822_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104715","article-title":"Novel strategies in breast cancer management: from treatment to long-term remission","author":"Habibi","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.bbrep.2026.102822_bib12","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2021.06.014","article-title":"VP7-2021: keynote-522: phase III study of neoadjuvant pembrolizumab+ chemotherapy vs. placebo+ chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC","volume":"32","author":"Schmid","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10265","key":"10.1016\/j.bbrep.2026.102822_bib13","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbrep.2026.102822_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.008","article-title":"LBA18 pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrep.2026.102822_bib15","article-title":"Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2026.102822_bib16","first-page":"1","article-title":"Toxicology of nanoparticles in drug delivery","author":"Sharma","year":"2021","journal-title":"Current pathobiology reports"},{"key":"10.1016\/j.bbrep.2026.102822_bib17","first-page":"445","article-title":"Enhancing drug penetration in solid tumors via nanomedicine: evaluation models, strategies and perspectives","volume":"32","author":"Shen","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bbrep.2026.102822_bib18","series-title":"Pharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems","first-page":"261","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","author":"Parmar","year":"2022"},{"issue":"5","key":"10.1016\/j.bbrep.2026.102822_bib19","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/anie.201912524","article-title":"Responsive exosome nano\u2010bioconjugates for synergistic cancer therapy","volume":"59","author":"Nie","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbrep.2026.102822_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biomaterials.2017.01.004","article-title":"Exosome-SIRP\u03b1, a CD47 blockade increases cancer cell phagocytosis","volume":"121","author":"Koh","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrep.2026.102822_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113620","article-title":"Engineered dendritic cells-derived extracellular vesicles for cancer immunotherapy","author":"Coelho","year":"2025","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","article-title":"Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer","volume":"21","author":"Huang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.bbrep.2026.102822_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1134\/S1990747816020112","article-title":"Exosomes: generation, structure, transport, biological activity, and diagnostic application","volume":"10","author":"Tamkovich","year":"2016","journal-title":"Biochemistry (Moscow) Supplement Series A: Membr. Cell Biol."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102822_bib25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.devcel.2013.04.003","article-title":"Viral infection controlled by a calcium-dependent lipid-binding module in ALIX","volume":"25","author":"Bissig","year":"2013","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbrep.2026.102822_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118623","article-title":"Exosomes: a new horizon in modern medicine","volume":"264","author":"Deb","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","article-title":"Emerging role of exosomes in cancer progression and tumor microenvironment remodeling","volume":"15","author":"Paskeh","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrep.2026.102822_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcdb.2015.02.010","article-title":"Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes","volume":"40","author":"Minciacchi","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bbrep.2026.102822_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0991-5","article-title":"Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance","volume":"18","author":"Mashouri","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrep.2026.102822_bib30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2022.05.027","article-title":"Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake","volume":"347","author":"Kimiz-Gebologlu","year":"2022","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12964-021-00730-1","article-title":"The exosome journey: from biogenesis to uptake and intracellular signalling","volume":"19","author":"Gurung","year":"2021","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bbrep.2026.102822_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112832","article-title":"Tumor-derived exosomes: the emerging orchestrators in melanoma","volume":"149","author":"Tan","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102822_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2217\/nnm-2022-0328","article-title":"Dual-targeting exosomes for improved drug delivery in breast cancer","volume":"18","author":"Tran","year":"2023","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib34","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1038\/s41467-020-18081-9","article-title":"ITGB3-mediated uptake of small extracellular vesicles facilitates intercellular communication in breast cancer cells","volume":"11","author":"Fuentes","year":"2020","journal-title":"Nat. Commun."},{"issue":"21\u201322","key":"10.1016\/j.bbrep.2026.102822_bib35","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1089\/ten.tea.2017.0158","article-title":"A systematic evaluation of factors affecting extracellular vesicle uptake by breast cancer cells","volume":"23","author":"Stranford","year":"2017","journal-title":"Tissue Eng."},{"issue":"6","key":"10.1016\/j.bbrep.2026.102822_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001874","article-title":"Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation","volume":"12","author":"Ridder","year":"2014","journal-title":"PLoS Biol."},{"issue":"10","key":"10.1016\/j.bbrep.2026.102822_bib37","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1074\/mcp.RA118.000644","article-title":"The impact of oncogenic EGFRvIII on the proteome of extracellular vesicles released from glioblastoma cells","volume":"17","author":"Choi","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molcel.2014.08.020","article-title":"Extracellular vesicles from neural stem cells transfer IFN-\u03b3 via Ifngr1 to activate Stat1 signaling in target cells","volume":"56","author":"Cossetti","year":"2014","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib39","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3390\/cancers12082179","article-title":"The biology of exosomes in breast cancer progression: dissemination, immune evasion and metastatic colonization","volume":"12","author":"Giordano","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s12276-023-01132-8","article-title":"Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications","volume":"56","author":"Jung","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib41","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","article-title":"The role of extracellular vesicles in cancer","volume":"186","author":"Kalluri","year":"2023","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bbrep.2026.102822_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024234","article-title":"Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading","volume":"6","author":"Koumangoye","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/cancers9080095","article-title":"Integrins and exosomes, a dangerous liaison in cancer progression","volume":"9","author":"Paolillo","year":"2017","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bbrep.2026.102822_bib44","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccr.2014.03.007","article-title":"Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis","volume":"25","author":"Zhou","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13046-022-02492-1","article-title":"The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy","volume":"41","author":"Qian","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.bbrep.2026.102822_bib46","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.3390\/ijms21165840","article-title":"Exosomes in angiogenesis and anti-angiogenic therapy in cancers","volume":"21","author":"Olejarz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrep.2026.102822_bib47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00011-020-01318-0","article-title":"Tumor-derived exosomes in the regulation of macrophage polarization","volume":"69","author":"Baig","year":"2020","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bbrep.2026.102822_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155666","article-title":"Exosomal microRNAs in cancer metastasis: a bridge between tumor micro and macroenvironment","author":"Saadh","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2017.1294368","article-title":"Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells","volume":"6","author":"Jong","year":"2017","journal-title":"J. Extracell. Vesicles"},{"issue":"31","key":"10.1016\/j.bbrep.2026.102822_bib51","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1038\/s41388-021-01896-1","article-title":"Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer","volume":"40","author":"Qiu","year":"2021","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.bbrep.2026.102822_bib52","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1039\/D0NR00523A","article-title":"Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer","volume":"12","author":"Li","year":"2020","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40364-022-00374-4","article-title":"Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications","volume":"10","author":"Hazrati","year":"2022","journal-title":"Biomarker Res."},{"key":"10.1016\/j.bbrep.2026.102822_bib54","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.2147\/IJN.S464249","article-title":"Engineering exosomes for therapeutic applications: decoding biogenesis, content modification, and cargo loading strategies","author":"Bahadorani","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"9","key":"10.1016\/j.bbrep.2026.102822_bib55","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/coatings13091660","article-title":"Surface modification of metallic nanoparticles for targeting drugs","volume":"13","author":"Abdelkawi","year":"2023","journal-title":"Coatings"},{"issue":"13","key":"10.1016\/j.bbrep.2026.102822_bib56","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"9","key":"10.1016\/j.bbrep.2026.102822_bib57","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib59","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1021\/acs.analchem.8b05204","article-title":"Aptamer-functionalized exosomes: elucidating the cellular uptake mechanism and the potential for cancer-targeted chemotherapy","volume":"91","author":"Zou","year":"2019","journal-title":"Anal. Chem."},{"issue":"12","key":"10.1016\/j.bbrep.2026.102822_bib60","doi-asserted-by":"crossref","first-page":"E1433","DOI":"10.1073\/pnas.1418401112","article-title":"Differential fates of biomolecules delivered to target cells via extracellular vesicles","volume":"112","author":"Kanada","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11010-019-03545-4","article-title":"Exosomes: cell-created drug delivery systems","volume":"459","author":"Familtseva","year":"2019","journal-title":"Mol. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.bbrep.2026.102822_bib62","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.top096271","article-title":"Electroporation","volume":"2019","author":"Kumar","year":"2019","journal-title":"Cold Spring Harb. Protoc."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib63","first-page":"147","article-title":"Irreversible electroporation: evolution of a laboratory technique in interventional oncology","volume":"20","author":"Deipolyi","year":"2014","journal-title":"Diagn. Interv. Radiol."},{"issue":"20A","key":"10.1016\/j.bbrep.2026.102822_bib64","article-title":"Electroporation-based therapies in the treatment of cancer","volume":"181","author":"Gehl","year":"2019","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.bbrep.2026.102822_bib65","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11165","article-title":"Transfection types, methods and strategies: a technical review","volume":"9","author":"Chong","year":"2021","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12195-016-0457-4","article-title":"Oncogene knockdown via active loading of small RNAs into extracellular vesicles by sonication","volume":"9","author":"Lamichhane","year":"2016","journal-title":"Cell. Mol. Bioeng."},{"issue":"11","key":"10.1016\/j.bbrep.2026.102822_bib67","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.3390\/pharmaceutics14112396","article-title":"Microbubble\u2013nanoparticle complexes for ultrasound-enhanced cargo delivery","volume":"14","author":"Chapla","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib68","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12964-024-01548-3","article-title":"Strategies for labelling of exogenous and endogenous extracellular vesicles and their application for in vitro and in vivo functional studies","volume":"22","author":"Boudna","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"17","key":"10.1016\/j.bbrep.2026.102822_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202300552","article-title":"Engineering extracellular vesicles as delivery systems in therapeutic applications","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib70","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1038\/s41467-024-49678-z","article-title":"Enhancing extracellular vesicle cargo loading and functional delivery by engineering protein-lipid interactions","volume":"15","author":"Peruzzi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrep.2026.102822_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155785","article-title":"Exosome-mediated delivery of CRISPR-Cas9: a revolutionary approach to cancer gene editing","volume":"266","author":"Balaraman","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbrep.2026.102822_bib72","article-title":"Exosomes-mediated CRISPR\/cas delivery: a cutting-edge frontier in cancer gene therapy","volume":"944","author":"Dhar","year":"2025","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib73","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ymthe.2025.09.045","article-title":"Extracellular vesicle-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells","volume":"34","author":"Ye","year":"2026","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib74","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s13346-025-01920-x","article-title":"Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer","volume":"16","author":"Aare","year":"2026","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.bbrep.2026.102822_bib75","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/IJN.S440619","article-title":"Engineered exosomes carrying miR-588 for treatment of triple negative breast cancer through remodeling the immunosuppressive microenvironment","author":"Zhang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrep.2026.102822_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2025.102635","article-title":"PH20-modified exosomes loaded curcumin inhibit desmoplastic breast cancer by breaking extracellular matrix barrier and normalizing cancer-associated fibroblasts","author":"Xue","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"18","key":"10.1016\/j.bbrep.2026.102822_bib77","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3390\/nano15181418","article-title":"Emerging strategies for cargo loading and engineering of extracellular vesicles for breast cancer treatment","volume":"15","author":"Mediratta","year":"2025","journal-title":"Nanomaterials"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib78","article-title":"Engineering hybrid exosomes by membrane fusion with liposomes","volume":"6","author":"Sato","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102822_bib79","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.tips.2024.02.006","article-title":"Genetically engineered loaded extracellular vesicles for drug delivery","volume":"45","author":"Erana-Perez","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib80","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12951-021-00986-2","article-title":"Artificial exosomes for translational nanomedicine","volume":"19","author":"Li","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.108647","article-title":"Recent progresses of exosome\u2013liposome fusions in drug delivery","volume":"35","author":"Zheng","year":"2024","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bbrep.2026.102822_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117485","article-title":"Exosome\/liposome hybrid nanovesicles for enhanced phototherapy and boosted anti-tumor immunity against melanoma","volume":"289","author":"Zhou","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bbrep.2026.102822_bib83","doi-asserted-by":"crossref","first-page":"16420","DOI":"10.1021\/acsami.2c22749","article-title":"Engineered cancer-derived small extracellular vesicle-liposome hybrid delivery system for targeted treatment of breast cancer","volume":"15","author":"Zhang","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"11","key":"10.1016\/j.bbrep.2026.102822_bib84","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3390\/pharmaceutics14112256","article-title":"Investigation of the antitumor activity and toxicity of tumor-derived exosomes fused with long-circulating and pH-sensitive liposomes containing doxorubicin","volume":"14","author":"Gomes","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrep.2026.102822_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125907","article-title":"Exosomes fused liposomes: formulation, stability studies and theranostic evaluation for breast cancer applications","volume":"682","author":"Verma","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.bbrep.2026.102822_bib86","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1021\/jacs.4c15534","article-title":"Pyridinium rotor strategy toward a robust photothermal agent for STING activation and multimodal image-guided immunotherapy for triple-negative breast cancer","volume":"147","author":"Ning","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib87","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1039\/D5RA04927J","article-title":"Hybrid exosomes: a rising horizon for precision cancer therapy","volume":"16","author":"Sonar","year":"2026","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12943-024-02215-4","article-title":"Emerging role of exosomes in cancer therapy: progress and challenges","volume":"24","author":"Li","year":"2025","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/bmm2.70045","article-title":"Advancing design strategies in smart stimulus\u2010responsive liposomes for drug release and nanomedicine","volume":"4","author":"Guo","year":"2026","journal-title":"BMEMat"},{"issue":"9","key":"10.1016\/j.bbrep.2026.102822_bib90","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1021\/acsnano.4c16854","article-title":"Surface components and biological interactions of extracellular vesicles","volume":"19","author":"Wang","year":"2025","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib91","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.bbrep.2026.102822_bib92","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.7150\/thno.112475","article-title":"Nano drug delivery systems for advanced immune checkpoint blockade therapy","volume":"15","author":"Guo","year":"2025","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib93","article-title":"Novel delivery systems for checkpoint inhibitors","volume":"6","author":"Lamichhane","year":"2019","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.bbrep.2026.102822_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1385484","article-title":"Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies","volume":"15","author":"Mantooth","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2026.102822_bib95","article-title":"PD-L1 siRNA theranostics with a dextran nanoparticle highlights the importance of nanoparticle delivery for effective tumor PD-L1 downregulation","volume":"10","author":"Pacheco-Torres","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1595","article-title":"Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine","volume":"12","author":"Chen","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.bbrep.2026.102822_bib97","article-title":"Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib98","doi-asserted-by":"crossref","first-page":"13703","DOI":"10.18632\/oncotarget.14626","article-title":"CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib99","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1189\/jlb.0206094","article-title":"Dendritic cell derived-exosomes: biology and clinical implementations","volume":"80","author":"Chaput","year":"2006","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.bbrep.2026.102822_bib100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1034\/j.1600-0854.2002.30502.x","article-title":"The biogenesis and functions of exosomes","volume":"3","author":"Stoorvogel","year":"2002","journal-title":"Traffic"},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib101","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4049\/jimmunol.1400703","article-title":"Dendritic cell-derived exosomes as immunotherapies in the fight against cancer","volume":"193","author":"Pitt","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbrep.2026.102822_bib102","article-title":"The involvement and application potential of exosomes in breast cancer immunotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2026.102822_bib103","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jconrel.2022.11.053","article-title":"Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies","volume":"353","author":"Li","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrep.2026.102822_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216989","article-title":"Exosome-based anticancer vaccines: from bench to bedside","volume":"595","author":"Zhao","year":"2024","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bbrep.2026.102822_bib105","article-title":"Exosome-like systems: from therapies to vaccination for cancer treatment and prevention-exploring the state of the art","volume":"12","author":"Sheikhhossein","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"21","key":"10.1016\/j.bbrep.2026.102822_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215318","article-title":"Targeting tumor-associated macrophages in cancer immunotherapy","volume":"13","author":"Petty","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrep.2026.102822_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1457491","article-title":"Reprogramming the tumor microenvironment - macrophages emerge as key players in breast cancer immunotherapy","volume":"15","author":"Sami","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib108","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrep.2026.102822_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213629","article-title":"Impaired function of dendritic cells within the tumor microenvironment","volume":"14","author":"Xiao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2026.102822_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114685","article-title":"Dendritic cell vaccines in breast cancer: immune modulation and immunotherapy","volume":"162","author":"Qian","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib111","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.4161\/onci.20982","article-title":"Targeting dendritic cells in situ for breast cancer immunotherapy","volume":"1","author":"Wang","year":"2012","journal-title":"Oncoimmunology"},{"issue":"13","key":"10.1016\/j.bbrep.2026.102822_bib112","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1182\/blood-2010-02-268425","article-title":"Targeting of DEC-205 on human dendritic cells results in efficient MHC class II\u2013restricted antigen presentation","volume":"116","author":"Birkholz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbrep.2026.102822_bib113","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102822_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1645","article-title":"Engineering exosomes to reshape the immune microenvironment in breast cancer: molecular insights and therapeutic opportunities","volume":"14","author":"Cao","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib115","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ymthe.2019.11.020","article-title":"Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy","volume":"28","author":"Shi","year":"2020","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib116","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-023-01382-y","article-title":"Engineered exosomes from different sources for cancer-targeted therapy","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrep.2026.102822_bib117","article-title":"NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bbrep.2026.102822_bib118","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.4049\/jimmunol.1101988","article-title":"Immune surveillance properties of human NK cell-derived exosomes","volume":"189","author":"Lugini","year":"2012","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib119","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer-natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrep.2026.102822_bib120","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fphar.2018.00735","article-title":"The advances and challenges in utilizing exosomes for delivering cancer therapeutics","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib121","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1172\/JCI84577","article-title":"Donor dendritic cell-derived exosomes promote allograft-targeting immune response","volume":"126","author":"Liu","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrep.2026.102822_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120888","article-title":"The protein corona hampers the transcytosis of transferrin-modified nanoparticles through blood-brain barrier and attenuates their targeting ability to brain tumor","volume":"274","author":"Xiao","year":"2021","journal-title":"Biomaterials"},{"issue":"23","key":"10.1016\/j.bbrep.2026.102822_bib123","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.2174\/0929867326666190129142604","article-title":"Exosome-like nanoparticles: a new type of nanocarrier","volume":"27","author":"Fernandes","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbrep.2026.102822_bib124","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ejps.2016.10.009","article-title":"Cell type-specific and common characteristics of exosomes derived from mouse cell lines: yield, physicochemical properties, and pharmacokinetics","volume":"96","author":"Charoenviriyakul","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.bbrep.2026.102822_bib125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2014.12.013","article-title":"Biodistribution and delivery efficiency of unmodified tumor-derived exosomes","volume":"199","author":"Smyth","year":"2015","journal-title":"J. Contr. Release"},{"issue":"11","key":"10.1016\/j.bbrep.2026.102822_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.201900111","article-title":"Chemical modulation of bioengineered exosomes for tissue\u2010specific biodistribution","volume":"2","author":"Hwang","year":"2019","journal-title":"Adv. Therapeut."},{"issue":"12","key":"10.1016\/j.bbrep.2026.102822_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2019.02.005","article-title":"Ticket to a bubble ride: cargo sorting into exosomes and extracellular vesicles","volume":"1867","author":"Anand","year":"2019","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102822_bib128","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ccr.2013.09.008","article-title":"Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis","volume":"24","author":"Ell","year":"2013","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib130","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.7150\/thno.39434","article-title":"Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs","volume":"10","author":"Qiao","year":"2020","journal-title":"Theranostics"},{"issue":"16","key":"10.1016\/j.bbrep.2026.102822_bib131","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1038\/s41388-017-0116-9","article-title":"Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379","volume":"37","author":"O'Brien","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrep.2026.102822_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1362681","article-title":"ExoDS: a versatile exosome-based drug delivery platform to target cancer cells and cancer stem cells","volume":"12","author":"Paul","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib132","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","article-title":"Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation","volume":"4","author":"Yang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bbrep.2026.102822_bib133","first-page":"692","article-title":"Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets","volume":"5","author":"Romagnoli","year":"2014","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib134","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acs.jproteome.7b00646","article-title":"Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes May mediate distinct immune suppressive functions","volume":"17","author":"Geis-Asteggiante","year":"2018","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbrep.2026.102822_bib135","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.canlet.2018.10.039","article-title":"Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit pancreatic ductal adenocarcinoma progression","volume":"442","author":"Ding","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrep.2026.102822_bib136","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1478-811X-11-88","article-title":"Exosomes are natural carriers of exogenous siRNA to human cells in vitro","volume":"11","author":"Shtam","year":"2013","journal-title":"Cell Commun. Signal."},{"issue":"6","key":"10.1016\/j.bbrep.2026.102822_bib137","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T cell therapy for breast cancer: from basic research to clinical application","volume":"18","author":"Yang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbrep.2026.102822_bib138","doi-asserted-by":"crossref","DOI":"10.4048\/jbc.2024.0262","article-title":"Utilizing miR-34a-Loaded HER2-Targeting exosomes to improve breast cancer treatment: insights from an animal model","volume":"28","author":"Sun","year":"2025","journal-title":"Journal of Breast Cancer"},{"key":"10.1016\/j.bbrep.2026.102822_bib139","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.actbio.2021.09.003","article-title":"Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis","volume":"135","author":"Hu","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbrep.2026.102822_bib140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.imlet.2021.08.004","article-title":"TLR ligand loaded exosome mediated immunotherapy of established mammary tumor in mice","volume":"239","author":"Yildirim","year":"2021","journal-title":"Immunol. Lett."},{"issue":"17","key":"10.1016\/j.bbrep.2026.102822_bib141","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade0625","article-title":"Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence","volume":"9","author":"Wu","year":"2023","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib142","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/0008-5472.CAN-17-2880","article-title":"Aptamer-conjugated extracellular nanovesicles for targeted drug delivery","volume":"78","author":"Wan","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bbrep.2026.102822_bib143","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.7150\/thno.16532","article-title":"Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer","volume":"7","author":"Wang","year":"2017","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bbrep.2026.102822_bib144","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","article-title":"A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy","volume":"35","author":"Tian","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrep.2026.102822_bib145","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.2147\/IJN.S210731","article-title":"Targeted delivery of doxorubicin to HER2 positive tumor models","author":"Gomari","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102822_bib146","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12187","article-title":"Robust delivery of RIG\u2010I agonists using extracellular vesicles for anti\u2010cancer immunotherapy","volume":"11","author":"Peng","year":"2022","journal-title":"J. Extracell. Vesicles"},{"issue":"4","key":"10.1016\/j.bbrep.2026.102822_bib147","first-page":"1","article-title":"Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer","volume":"42","author":"Alfawaz Altamimi","year":"2025","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib148","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6690704","article-title":"Canine natural killer cell\u2010derived exosomes exhibit antitumor activity in a mouse model of canine mammary tumor","volume":"2021","author":"Lee","year":"2021","journal-title":"BioMed Res. Int."},{"issue":"10","key":"10.1016\/j.bbrep.2026.102822_bib149","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3390\/cancers13102397","article-title":"Therapeutic silencing of BCL-2 using NK cell-derived exosomes as a novel therapeutic approach in breast cancer","volume":"13","author":"Kaban","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrep.2026.102822_bib150","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jconrel.2023.10.007","article-title":"Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy","volume":"363","author":"Tao","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrep.2026.102822_bib151","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biomaterials.2018.05.048","article-title":"Development and MPI tracking of novel hypoxia-targeted theranostic exosomes","volume":"177","author":"Jung","year":"2018","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.bbrep.2026.102822_bib152","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-17-0827","article-title":"Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"issue":"4","key":"10.1016\/j.bbrep.2026.102822_bib153","first-page":"963","article-title":"Folic acid-modified Exosome-PH20 enhances the efficiency of therapy via modulation of the tumor microenvironment and directly inhibits tumor cell metastasis","volume":"6","author":"Feng","year":"2021","journal-title":"Bioact. Mater."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib154","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2019.1670893","article-title":"Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103+ dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity","volume":"8","author":"Hong","year":"2019","journal-title":"J. Extracell. Vesicles"},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/mt.2012.180","article-title":"Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells","volume":"21","author":"Ohno","year":"2013","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbrep.2026.102822_bib156","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s12010-018-2813-4","article-title":"Engineered exosomes for targeted transfer of siRNA to HER2 positive breast cancer cells","volume":"187","author":"Limoni","year":"2019","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.bbrep.2026.102822_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104262","article-title":"The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth","volume":"360","author":"Yang","year":"2021","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bbrep.2026.102822_bib158","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.omtn.2021.10.009","article-title":"Smart exosomes with lymph node homing and immune-amplifying capacities for enhanced immunotherapy of metastatic breast cancer","volume":"26","author":"Ji","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"9","key":"10.1016\/j.bbrep.2026.102822_bib159","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1016\/j.ymthe.2022.06.013","article-title":"Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes","volume":"30","author":"Cheng","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrep.2026.102822_bib160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jconrel.2023.11.051","article-title":"OX40L-expressing M1-like macrophage exosomes for cancer immunotherapy","volume":"365","author":"Yu","year":"2024","journal-title":"J. Contr. Release"},{"issue":"10","key":"10.1016\/j.bbrep.2026.102822_bib161","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/cancers18101619","article-title":"Therapeutically engineering exosomes to target CD206+ M2 macrophages to prevent the development of primary tumors and distal metastases in breast cancers","volume":"18","author":"Parvin","year":"2026","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bbrep.2026.102822_bib162","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13367","article-title":"Preparation and characterization of extracellular vesicles","volume":"85","author":"Tiwari","year":"2021","journal-title":"Am. J. Reprod. Immunol."},{"issue":"10","key":"10.1016\/j.bbrep.2026.102822_bib163","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/cells12101416","article-title":"Current strategies for exosome cargo loading and targeting delivery","volume":"12","author":"Zeng","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bbrep.2026.102822_bib164","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3390\/ijms24032496","article-title":"Recent advances on surface-modified GBM targeted nanoparticles: targeting strategies and surface characterization","volume":"24","author":"Rod\u00e0","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"33","key":"10.1016\/j.bbrep.2026.102822_bib165","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202403199","article-title":"Immunogenicity of extracellular vesicles","volume":"36","author":"Xia","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bbrep.2026.102822_bib166","series-title":"Public Safety Notification on Exosome Products","author":"Food","year":"2019"},{"issue":"8","key":"10.1016\/j.bbrep.2026.102822_bib167","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/pharmaceutics14081684","article-title":"Practical considerations for translating mesenchymal stromal cell-derived extracellular vesicles from bench to bed","volume":"14","author":"Lui","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580826003821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580826003821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:04:55Z","timestamp":1793973895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580826003821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":167,"alternative-id":["S2405580826003821"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2026.102822","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered exosomes for breast cancer immunotherapy: Emerging strategies and translational potential","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2026.102822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102822"}}